share_log

Chardan Capital Maintains Buy on Seres Therapeutics, Lowers Price Target to $8

Chardan Capital Maintains Buy on Seres Therapeutics, Lowers Price Target to $8

Chardan Capital維持對Seres Therapeutics的買入,將目標股價下調至8美元
Moomoo 24/7 ·  03/06 07:38

Chardan Capital analyst Keay Nakae maintains Seres Therapeutics (NASDAQ:MCRB) with a Buy and lowers the price target from $10 to $8.

Chardan Capital分析師Keay Nakae維持Seres Therapeutics(納斯達克股票代碼:MCRB)的買入並將目標股價從10美元下調至8美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論